Publication | Closed Access

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Phase Ii EvaluationMedicineCancer ManagementGynecologyWeekly PaclitaxelFallopian TubePharmacotherapyCancer TreatmentOncologyRadiation OncologyGynecology OncologyOvarian Cancer